|Bid||12.14 x 800|
|Ask||12.17 x 800|
|Day's range||12.00 - 12.23|
|52-week range||3.00 - 13.66|
|Beta (5Y monthly)||1.86|
|PE ratio (TTM)||N/A|
|Earnings date||03 May 2023 - 08 May 2023|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||13 Dec 2019|
|1y target est||4.00|
CAMBRIDGE, Mass., March 09, 2023--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2022 financial results for the period ended December 31, 2022.
We can readily understand why investors are attracted to unprofitable companies. For example, Merrimack Pharmaceuticals...
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...